Learn what zavegepant is, how this intranasal CGRP receptor antagonist differs from traditional triptans, and review key clinical trial evidence on its speed, effectiveness, and safety for acute migraine treatment.
Learn how zavegepant, the first intranasal CGRP receptor antagonist, offers fast-acting, targeted relief for acute migraine—especially for patients who can’t tolerate oral medications or need rapid onset of action.